stars 1 stars 2 stars 3

Oncimmune has developed the most advanced and comprehensive analytical platform for the discovery of Antibody / Autoantibody Biomarker Signatures. ImmunoINSIGHTS™, the best-in-class biomarker discovery engine, provides access to the B cell repertoire and a pivotal class of biomarkers. With one of the world’s largest antigen libraries covering 9000+ human antigens and multi-species variants, we profile antibodies from various biologic samples in very low volume (50 µl). Developed and curated by immunologists and a team of bioinformaticians, we offer high content biological insights and analytics powered by proprietary machine learning algorithms, models and deep knowledge mining solutions. Our platform uses Luminex xMAP® – the world’s most used multiplexing technology. At Oncimmune, our mission is to develop innovative technologies and solutions to improve the understanding of the immune system leading to more effective, targeted and safer treatments and better diagnosis. Our scientists work hand-in-hand with our clients to discover relevant and insightful biomarkers.

Oncimmune Questions

The Oncimmune annual revenue was $19.9 million in 2026.

Jacek Koszalka is the Director of Quality and Regulatory Affairs of Oncimmune.

23 people are employed at Oncimmune.

Oncimmune is based in Cambridge, Massachusetts.

The NAICS codes for Oncimmune are [3254, 32, 325, 32541].

The SIC codes for Oncimmune are [283, 28].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users